Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 8.29% and Operating profit at 7.45% over the last 5 years
2
Negative results in Mar 26
3
With ROE of 12.08%, it has a fair valuation with a 2.29 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,740 Million (Large Cap)
18.00
NA
2.84%
-0.36
12.08%
2.33
Revenue and Profits:
Net Sales:
573 Million
(Quarterly Results - Jun 2026)
Net Profit:
276 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.89%
0%
2.89%
6 Months
-14.46%
0%
-14.46%
1 Year
-24.61%
0%
-24.61%
2 Years
7.67%
0%
7.67%
3 Years
-20.3%
0%
-20.3%
4 Years
-7.98%
0%
-7.98%
5 Years
-40.1%
0%
-40.1%
Tibet Cheezheng Tibetan Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.29%
EBIT Growth (5y)
7.45%
EBIT to Interest (avg)
10.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.40
Tax Ratio
12.17%
Dividend Payout Ratio
52.81%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.17%
ROE (avg)
15.58%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.12
EV to EBIT
14.93
EV to EBITDA
12.68
EV to Capital Employed
2.73
EV to Sales
3.67
PEG Ratio
0.90
Dividend Yield
5.00%
ROCE (Latest)
18.31%
ROE (Latest)
12.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
572.70
772.00
-25.82%
Operating Profit (PBDIT) excl Other Income
286.30
300.70
-4.79%
Interest
2.10
14.50
-85.52%
Exceptional Items
16.30
24.70
-34.01%
Consolidate Net Profit
276.20
284.40
-2.88%
Operating Profit Margin (Excl OI)
435.00%
341.60%
9.34%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -25.82% vs 22.68% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -2.88% vs 24.52% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,389.80
2,311.20
3.40%
Operating Profit (PBDIT) excl Other Income
743.60
675.50
10.08%
Interest
48.10
60.40
-20.36%
Exceptional Items
67.50
105.10
-35.78%
Consolidate Net Profit
647.50
581.40
11.37%
Operating Profit Margin (Excl OI)
251.90%
231.50%
2.04%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.40% vs 14.49% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.37% vs 0.38% in Dec 2024
About Tibet Cheezheng Tibetan Medicine Co., Ltd. 
Tibet Cheezheng Tibetan Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






